Pharmaceutical care in Alzheimer's disease

  • Sandra Vezmar Kovačević Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade - Faculty of Pharmacy
Keywords: Alzheimer's disease, pharmaceutical care, drug-drug interactions, adverse reactions, adherence

Abstract


Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory and cognitive function impairment as well as behavioural and psychiatric disturbances. Pharmaceutical care involves the process of identifying, resolving, and preventing drug-related problems, and it is aimed at improving the patient’s quality of life. AD is usually diagnosed in elderly patients with comorbidities and, consequently, a variety of drug-related problems may occur. Pharmacists should focus on adverse reactions, drug-drug interactions, and adherence in patients with AD. The introduction of acetylcholinesterase inhibitors in treatment may be associated with adverse effects, such as diarrhoea, muscle cramps, fatigue, nausea, vomiting, insomnia, anorexia, headache, and dizziness, which may be transient or require an alternative medication. Use of anticholinergic medications, bradycardia causing medications, antipsychotics and other medications should be assessed carefully because of potential drug-drug interactions with acetylcholinesterase inhibitors, especially rivastigmine. Adherence may be a major drug-related problem in patients with AD because of the nature of illness and appropriate communication between pharmacists and patients or carers requiring adequate skills and knowledge. Although AD is increasing in prevalence there is a lack of evidence about the impact of pharmaceutical care on the treatment outcomes and quality of life of patients and more research is needed in this area.

References

Epperly T, Dunay MA, Boice JL. Alzheimers disease: pharmacologic and nonpharmacologic therapies for cognitive and functional symptoms. Am Fam Physicia 2017; 95(12):771-778.

Mc Khann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJ, Kawas CH et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):263-269.

World Alzheimer Report 2018. The state of the art of dementia research: New frontiers. Alzheimer’s Disease International, London, UK. Available at:

https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement 2007;3(3):186-191

Skelton, JB. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease. J Am Pharm Assoc (2003) 2008;48(6):715–721.

NHS Education for Scotland. The Pharmaceutical Care of People with Dementia https://www.nes.scot.nhs.uk/media/4104909/pharmaceutical-care-of-people-with-dementia-2014.pdf

Hepler CD, Strand LM. Opportunities and Responsibilities in Pharmaceutical Care. Am J Pharm Educ 1989;53(suppl):7S-15S

Hepler CD, Strand LM. Opportunities and Responsibilities in Pharmaceutical Care. Am J Hosp Pharm 1990;47(3):533-543.

European Directorate for the Quality of Medicines and HealthCare (EDQM). Pharmaceutical Care Policies and Practices for a Safer, More Responsible and Cost-effective Health System https://www.edqm.eu/medias/fichiers/policies_and_practices_for_a_safer_more_responsibl.pdf

Pharmaceutical Care Network Europe (PCNE). https://www.pcne.org/working-groups/2/drug-related-problem-classification

Yaghmour SM, Bartlett R, Brannelly T. Dementia in Eastern Mediterranean countries: A systematic review. Dementia (London) 2019;18(7-8):2635-2661.

Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 2013;168(2): 934-945.

Forouhi NG, Wareham NJ. Epidemiology of diabetes. Medicine (Abingdone) 2014;42(12):698-702

Bushardt RL, Massey EB, Simpson TW, Ariail JC, Simpson KN. Polypharmacy: Misleading, but manageable. Clin Interv Aging 2008;3(2):383-389.

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017;17(1): 230.

Brady R, Weinman J. Adherence to cholinesterase inhibitors in Alzheimer’s disease: A review. Dement Geriatr Cogn Disord 2013;35(5-6);351-363.

Small G, Dubois B. A review of compliance to treatment in Alzheimer’s disease: Potential benefits of a transdermal patch. Curr Med Res Opin 2007;23(11):2705-2713.

Chisholm-Burns MA, Spivey CA. The “cost” of medication nonadherence: Consequences we cannot afford to accept. J Am Pharm Assoc (2003) 2012;52(6): 823-826.

Taylor D. Dementia. In Clinical Pharmacy and Therapeutics, eds. Whittlesea C, Hodon K. 6th ed, Elsevier. 2019, pp 557-579.

Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International, London, UK. Available at: https://www.alz.co.uk/research/world-report-2015

Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement 2017;13:325-373.

National Institute for Health and Care Excellence (NICE), 2016. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease. Technology appraisal guidance [TA217]. Available at: https://www.nice.org.uk/guidance/ta217.

Hermann N, Li A, Lanctôt K. Memantine in dementia: a review of the current evidence. Expert Opin. Pharmacother. 2011;12(5):787–800.

Lexi-interact® Lexi-Comp Inc. Available at: https://online.lexi.com

Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer’s disease? A number needed to treat analysis. Int J Geriatr Psych 2000;15(3):203–207.

Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR.. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003;51(7): 937–944.

Wang PS, Schneeweiss S, Avorn J, Fischer MA; Mogun H, Solomon D, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22): 2335–2341.

Fox C, Livingston G, Maidment ID, Coulton S, Smithard DG, Boustani M, et al. The impact of anticholinergic burden in Alzheimer’s dementia – the Laser-AD study. Age Ageing 2011;40(6):730–735.

Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009 (1), Art. No. CD003120. https://doi:10.1002/14651858.CD003120.pub3.

Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. J Gen Intern. Med 2005;20(7):657–666.

Farina N, Isaac, MG, Clark AR, Rusted J, Tabet N. The use of vitamin E for Alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 2012 (11) Art No., CD002854. https://doi:10.1002/14651858.CD 002854.pub3.

National Institute for Health and Care Excellence, Social Care Institute for Excellence (NICE-SCIE), 2011. The NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Available at: https://www.nice.org.uk/guidance/cg42/.

Eska K, Graessel E, Donath C, Schwarzkopf L, Lauterberg J, Holle R. Predictors of institutionalization of dementia patients in mild and moderate stages: a 4-year prospective analysis. Dement Geriatr Cogn Dis Extra 2013;3(1):426–445.

Alzubaidi H, Saidawi W, Hussein A, Hasan S. Critical role of pharmacists in caring for Alzheimer’s disease patients. J Alzheimers Dis 2020;73(3):1253-1264.

Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol 2017;18: 52.

Published
2020/05/15
Section
Review articles